World · India Bureau
Sun Pharma, Eight Drugmakers Accept US Pricing Agreements
India's leading pharmaceutical companies have signed pricing accords with the Trump administration as it accelerates efforts to impose most-favoured-nation pricing across the industry. The agreements signal growing acceptance among mid-sized manufacturers of the new regulatory framework.
LSN India ·
Sun Pharmaceutical and eight other drugmakers have reached pricing agreements with the Trump administration, marking a significant development in the US government's push to control pharmaceutical costs through a most-favoured-nation (MFN) pricing model.
The accords represent a strategic shift in how the administration is approaching drug pricing regulation, moving beyond initial pressures on major pharmaceutical corporations to include mid-sized manufacturers. Industry sources indicate the agreements establish pricing structures that align with the administration's stated objective of ensuring US patients pay prices comparable to those in other developed nations.
Sun Pharma, India's largest pharmaceutical company by market capitalisation, joins other manufacturers in accepting the new pricing regime. The company's participation underscores the global reach of US pharmaceutical pricing policies and their impact on Indian drugmakers with significant US market presence.
The agreements come as the Trump administration intensifies its broader MFN pricing initiative, which has faced both industry resistance and legal challenges. By securing commitments from multiple mid-sized manufacturers, the administration appears to be consolidating support for its pricing framework ahead of potential regulatory changes.
Analysts note the agreements may influence pricing strategies across the broader pharmaceutical industry, particularly for Indian generic manufacturers who supply substantial volumes to the US market. The long-term implications for drug pricing and availability remain subject to ongoing regulatory and legislative developments.